Press Resease

Opioid Tolerance Treatment Market by Drug (Alpha2-Adrenoceptor Agonists, NMDA Antagonists, and Others), by Opioid Tolerance Type (Innate Tolerance and Acquired Tolerance), by Administration Route (Enteral and Parenteral), and by End-User (Hospitals & ASCs, Rehabilitation Centers, and Others): Global Market Perspective, Comprehensive Analysis, and Forecast, 2018–2025

Published Date: 04-Jul-2019 Category: Pharmaceutical Report Format : PDF Pages: 120 Report Code: ZMR-4315 Status : Published

Global opioid tolerance treatment market expected to generate USD 2,290 million by 2025, at a CAGR of 3.6% between 2019 and 2025. The increasing number of orthopedic surgeries is one of the main growth drivers of the global opioid tolerance treatment market.

Description

The report covers a forecast and an analysis of the global opioid tolerance treatment market on a global and regional level. The study provides historical data for 2017 and 2018 along with a forecast from 2019 to 2025 based on revenue (USD Million). The study includes drivers and restraints of the global opioid tolerance treatment market along with their impact on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the global opioid tolerance treatment market on a global level.

In order to give the users of this report a comprehensive view of the global opioid tolerance treatment market, we have included a competitive landscape and an analysis of Porter’s Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein all the segments are benchmarked based on their market size, growth rate, and general attractiveness.

Global Opioid Tolerance Treatment Market

The report provides company market share analysis to give a broader overview of the key players in the market. In addition, the report also covers key strategic developments of the market including acquisitions & mergers, new launch, agreements, partnerships, collaborations & joint ventures, research & development, and regional expansion of major participants involved in the market on a global and regional basis.

The study provides a decisive view of the global opioid tolerance treatment market is divided based on drug, administration route, opioid tolerance type, end-user, and region. The regional segment includes North America, Latin America, Asia Pacific, Europe, and the Middle East and Africa.

Some major players operating in the global opioid tolerance treatment market are Pfizer, GlaxoSmithKline, Boehringer Ingelheim, Teva Pharmaceutical, Mylan, Otsuka Pharmaceutical, Johnson & Johnson, Aurobindo Pharma, Acorda Therapeutics, and Zydus Cadila.

This report segments the global opioid tolerance treatment market into:

Global Opioid Tolerance Treatment Market: Drug Analysis

  • NMDA Antagonists
    • Ketamine
    • Dextromethorphan
    • Others
  • Alpha2-Adrenoceptor Agonists
    • Clonidine
    • Tizanidine
    • Others
  • Others

Global Opioid Tolerance Treatment Market: Opioid Tolerance Type Analysis

  • Innate Tolerance
  • Acquired Tolerance

Global Opioid Tolerance Treatment Market: Administration Route Analysis

  • Enteral
  • Parenteral

Global Opioid Tolerance Treatment Market: End-User Analysis

  • Hospitals and ASCs
  • Rehabilitation Centers
  • Others (Homecare Settings and Research Institutes)

Global Opioid Tolerance Treatment Market: Regional Analysis

  • North America
    • The U.S.
  • Europe
    • UK
    • France
    • Germany
  • Asia Pacific
    • China
    • Japan
    • India
  • Latin America
    • Brazil
  • Middle East and Africa

Table Of Content

  • Chapter 1. Introduction
    • 1.1. Report description and scope
    • 1.2. Research scope
    • 1.3. Research methodology
      • 1.3.1. Market research process
      • 1.3.2. Market research methodology
  •  
  • Chapter 2. Executive Summary
    • 2.1. Global Opioid Tolerance Treatment Market, 2017-2025 (USD Million)
    • 2.2. Global Opioid Tolerance Treatment Market: Snapshot
  •  
  • Chapter 3. Global Opioid Tolerance Treatment Market - Industry Analysis
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising consumption of opioids for medical and non-medical purposes
      • 3.2.2. An increasing number of opioid prescriptions for therapeutic purposes
    • 3.3. Market Restraints
      • 3.3.1. Stringent procedures and protocols in the medical field
    • 3.4. Opportunities
      • 3.4.1. Government Funding and Support
    • 3.5. Porter's Five Forces Analysis
    • 3.6. Market Attractiveness Analysis
      • 3.6.1.
      • Market attractiveness analysis, by Drug
      • 3.6.2. Market attractiveness analysis, by opioid tolerance type
      • 3.6.3. Market attractiveness analysis, by administration route
      • 3.6.4. Market attractiveness analysis, by end-user
      • 3.6.5.
      • Market attractiveness analysis, by region
  •  
  • Chapter 4. Global Opioid Tolerance Treatment Market - Competitive Landscape
    • 4.1. Company market share analysis
      • 4.1.1. Global Opioid Tolerance Treatment Market: company market share, 2018
    • 4.2. Strategic development
      • 4.2.1. Acquisitions & mergers
      • 4.2.2. New therapy launch
      • 4.2.3. Agreements, partnerships, collaborations, and joint ventures
      • 4.2.4. Research and development and regional expansion
  •  
  • Chapter 5. Global Opioid Tolerance Treatment Market - Drug Analysis
    • 5.1. Global Opioid Tolerance Treatment Market: Drug overview
      • 5.1.1. Global Opioid Tolerance Treatment Market Revenue share, by Drug, 2018 and 2025
    • 5.2. NMDA Antagonists
      • 5.2.1. Global Opioid Tolerance Treatment Market for NMDA Antagonists, 2017-2025 (USD Million)
    • 5.3. Alpha2-Adrenoceptor Agonists
      • 5.3.1. Global Opioid Tolerance Treatment Market for Alpha2-Adrenoceptor Agonists, 2017-2025 (USD Million)
    • 5.4. Others
      • 5.4.1. Global Opioid Tolerance Treatment Market for others, 2017-2025 (USD Million)
  •  
  • Chapter 6. Global Opioid Tolerance Treatment Market - Opioid Tolerance Type Analysis
    • 6.1. Global Opioid Tolerance Treatment Market: Opioid Tolerance Type
      • 6.1.1. Global Opioid Tolerance Treatment Market Revenue share, by Opioid Tolerance Type, 2018 and 2025
    • 6.2. Innate Tolerance
      • 6.2.1. Global Opioid Tolerance Treatment Market for Innate Tolerance, 2017-2025 (USD Million)
    • 6.3. Acquired Tolerance
      • 6.3.1. Global Opioid Tolerance Treatment Market for Acquired Tolerance, 2017-2025 (USD Million)
  •  
  • Chapter 7. Global Opioid Tolerance Treatment Market - Administration Route Segment Analysis
    • 7.1. Global Opioid Tolerance Treatment Market: Administration Route overview
      • 7.1.1. Global Opioid Tolerance Treatment Market revenue share, by Administration Route, 2018 and 2025
    • 7.2. Enteral
      • 7.2.1. Global Opioid Tolerance Treatment Market for Enteral, 2017-2025 (USD Million)
    • 7.3. Parenteral
      • 7.3.1. Global Opioid Tolerance Treatment Market for Parenteral, 2017-2025 (USD Million)
  •  
  • Chapter 8. Global Opioid Tolerance Treatment Market - End-User Analysis
    • 8.1. Global Opioid Tolerance Treatment Market: End-User overview
      • 8.1.1. Global Opioid Tolerance Treatment Market revenue share, by End-User, 2018 and 2025
    • 8.2. Hospitals & ASCs
      • 8.2.1. Global Opioid Tolerance Treatment Market for Hospitals & ASCs, 2017-2025 (USD Million)
    • 8.3. Rehabilitation Centers
      • 8.3.1. Global Opioid Tolerance Treatment Market for Rehabilitation Centers, 2017-2025 (USD Million)
    • 8.4. Others
      • 8.4.1. Global Opioid Tolerance Treatment Market for Others, 2017-2025 (USD Million)
  •  
  • Chapter 9. Global Opioid Tolerance Treatment Market - Regional Analysis
    • 9.1. Global Opioid Tolerance Treatment Market: regional overview
      • 9.1.1. Global Opioid Tolerance Treatment Market Revenue share, by region, 2018 and 2025
    • 9.2. North America
      • 9.2.1. North America Opioid Tolerance Treatment Market Revenue, by Drug, 2017-2025 (USD Million)
      • 9.2.2. North America Opioid Tolerance Treatment Market Revenue, by Opioid Tolerance Type, 2017-2025 (USD Million)
      • 9.2.3. North America Opioid Tolerance Treatment Market Revenue, by Administration Route, 2017-2025 (USD Million)
      • 9.2.4. North America Opioid Tolerance Treatment Market Revenue, by end-user, 2017-2025 (USD Million)
      • 9.2.5. The U.S.
        • 9.2.5.1. The U.S. Opioid Tolerance Treatment Market Revenue, by Drug, 2017-2025 (USD Million)
        • 9.2.5.2. The U.S. Opioid Tolerance Treatment Market Revenue, by Opioid Tolerance Type, 2017-2025 (USD Million)
        • 9.2.5.3. The U.S. Opioid Tolerance Treatment Market Revenue, by Administration Route, 2017-2025 (USD Million)
        • 9.2.5.4. The U.S. Opioid Tolerance Treatment Market Revenue, by End-User, 2017-2025 (USD Million)
      • 9.2.6. Rest of North America
        • 9.2.6.1. Rest of North America Opioid Tolerance Treatment Market Revenue, by Drug, 2017-2025 (USD Million)
        • 9.2.6.2. Rest of North America Opioid Tolerance Treatment Market Revenue, by Opioid Tolerance Type, 2017-2025 (USD Million)
        • 9.2.6.3. Rest of North America Opioid Tolerance Treatment Market Revenue, by Administration Route, 2017-2025 (USD Million)
        • 9.2.6.4. Rest of North America Opioid Tolerance Treatment Market Revenue, by End-User, 2017-2025 (USD Million)
    • 9.3. Europe
      • 9.3.1. Europe Opioid Tolerance Treatment Market Revenue, by Drug, 2017-2025 (USD Million)
      • 9.3.2. Europe Opioid Tolerance Treatment Market Revenue, by Opioid Tolerance Type, 2017-2025 (USD Million)
      • 9.3.3. Europe Opioid Tolerance Treatment Market Revenue, by Administration Route, 2017-2025 (USD Million)
      • 9.3.4. Europe Opioid Tolerance Treatment Market Revenue, by End-User, 2017-2025 (USD Million)
      • 9.3.5. UK
        • 9.3.5.1. UK Opioid Tolerance Treatment Market Revenue, by Drug, 2017-2025 (USD Million)
        • 9.3.5.2. UK Opioid Tolerance Treatment Market Revenue, by Opioid Tolerance Type, 2017-2025 (USD Million)
        • 9.3.5.3. UK Opioid Tolerance Treatment Market Revenue, by Administration Route, 2017-2025 (USD Million)
        • 9.3.5.4. UK Opioid Tolerance Treatment Market Revenue, by End-User, 2017-2025 (USD Million)
      • 9.3.6. Germany
        • 9.3.6.1. Germany Opioid Tolerance Treatment Market Revenue, by Drug, 2017-2025 (USD Million)
        • 9.3.6.2. Germany Opioid Tolerance Treatment Market Revenue, by Opioid Tolerance Type, 2017-2025 (USD Million)
        • 9.3.6.3. Germany Opioid Tolerance Treatment Market Revenue, by Administration Route, 2017-2025 (USD Million)
        • 9.3.6.4. Germany Opioid Tolerance Treatment Market Revenue, by End-User, 2017-2025 (USD Million)
      • 9.3.7. France
        • 9.3.7.1. France Opioid Tolerance Treatment Market Revenue, by Drug, 2017-2025 (USD Million)
        • 9.3.7.2. France Opioid Tolerance Treatment Market Revenue, by Opioid Tolerance Type, 2017-2025 (USD Million)
        • 9.3.7.3. France Opioid Tolerance Treatment Market Revenue, by Administration Route, 2017-2025 (USD Million)
        • 9.3.7.4. France Opioid Tolerance Treatment Market Revenue, by End-User, 2017-2025 (USD Million)
      • 9.3.8. Rest of Europe
        • 9.3.8.1. Rest of Europe Opioid Tolerance Treatment Market Revenue, by Drug, 2017-2025 (USD Million)
        • 9.3.8.2. Rest of Europe Opioid Tolerance Treatment Market Revenue, by Opioid Tolerance Type, 2017-2025 (USD Million)
        • 9.3.8.3. Rest of Europe Opioid Tolerance Treatment Market Revenue, by Administration Route, 2017-2025 (USD Million)
        • 9.3.8.4. Rest of Europe Opioid Tolerance Treatment Market Revenue, by End-User, 2017-2025 (USD Million)
    • 9.4. Asia Pacific
      • 9.4.1. Asia Pacific Opioid Tolerance Treatment Market Revenue, by Drug, 2017-2025 (USD Million)
      • 9.4.2. Asia Pacific Opioid Tolerance Treatment Market Revenue, by Opioid Tolerance Type, 2017-2025 (USD Million)
      • 9.4.3. Asia Pacific Opioid Tolerance Treatment Market Revenue, by Administration Route, 2017-2025 (USD Million)
      • 9.4.4. Asia Pacific Opioid Tolerance Treatment Market Revenue, by End-User, 2017-2025 (USD Million)
      • 9.4.5. China
        • 9.4.5.1. China Opioid Tolerance Treatment Market Revenue, by Drug, 2017-2025 (USD Million)
        • 9.4.5.2. China Opioid Tolerance Treatment Market Revenue, by Opioid Tolerance Type, 2017-2025 (USD Million)
        • 9.4.5.3. China Opioid Tolerance Treatment Market Revenue, by Administration Route, 2017-2025 (USD Million)
        • 9.4.5.4. China Opioid Tolerance Treatment Market Revenue, by End-User, 2017-2025 (USD Million)
      • 9.4.6. Japan
        • 9.4.6.1. Japan Opioid Tolerance Treatment Market Revenue, by Drug, 2017-2025 (USD Million)
        • 9.4.6.2. Japan Opioid Tolerance Treatment Market Revenue, by Opioid Tolerance Type, 2017-2025 (USD Million)
        • 9.4.6.3. Japan Opioid Tolerance Treatment Market Revenue, by Administration Route, 2017-2025 (USD Million)
        • 9.4.6.4. Japan Opioid Tolerance Treatment Market Revenue, by End-User, 2017-2025 (USD Million)
      • 9.4.7. India
        • 9.4.7.1. India Opioid Tolerance Treatment Market Revenue, by Drug, 2017-2025 (USD Million)
        • 9.4.7.2. India Opioid Tolerance Treatment Market Revenue, by Opioid Tolerance Type, 2017-2025 (USD Million)
        • 9.4.7.3. India Opioid Tolerance Treatment Market Revenue, by Administration Route, 2017-2025 (USD Million)
        • 9.4.7.4. India Opioid Tolerance Treatment Market Revenue, by End-User, 2017-2025 (USD Million)
      • 9.4.8. Rest of Asia Pacific
        • 9.4.8.1. Rest of Asia Pacific Opioid Tolerance Treatment Market Revenue, by Drug, 2017-2025 (USD Million)
        • 9.4.8.2. Rest of Asia Pacific Opioid Tolerance Treatment Market Revenue, by Opioid Tolerance Type, 2017-2025 (USD Million)
        • 9.4.8.3. Rest of Asia Pacific Opioid Tolerance Treatment Market Revenue, by Administration Route, 2017-2025 (USD Million)
        • 9.4.8.4. Rest of Asia Pacific Opioid Tolerance Treatment Market Revenue, by End-User, 2017-2025 (USD Million)
    • 9.5. Latin America
      • 9.5.1. Latin America Opioid Tolerance Treatment Market Revenue, by Drug, 2017-2025 (USD Million)
      • 9.5.2. Latin America Opioid Tolerance Treatment Market Revenue, by Opioid Tolerance Type, 2017-2025 (USD Million)
      • 9.5.3. Latin Global Opioid Tolerance Treatment Market Revenue, by Administration Route, 2017-2025 (USD Million)
      • 9.5.4. Latin Global Opioid Tolerance Treatment Market Revenue, by End-User, 2017-2025 (USD Million)
      • 9.5.5. Brazil
        • 9.5.5.1. Brazil Global Opioid Tolerance Treatment Market Revenue, by Drug, 2017-2025 (USD Million)
        • 9.5.5.2. Brazil Global Opioid Tolerance Treatment Market Revenue, by Opioid Tolerance Type, 2017-2025 (USD Million)
        • 9.5.5.3. Brazil Global Opioid Tolerance Treatment Market Revenue, by Administration Route, 2017-2025 (USD Million)
        • 9.5.5.4. Brazil Global Opioid Tolerance Treatment Market Revenue, by End-User, 2017-2025 (USD Million)
      • 9.5.6. Rest of Latin America
        • 9.5.6.1. Rest of Latin America Opioid Tolerance Treatment Market Revenue, by Drug, 2017-2025 (USD Million)
        • 9.5.6.2. Rest of Latin America Opioid Tolerance Treatment Market Revenue, by Opioid Tolerance Type, 2017-2025 (USD Million)
        • 9.5.6.3. Rest of Latin America Opioid Tolerance Treatment Market Revenue, by Administration Route, 2017-2025 (USD Million)
        • 9.5.6.4. Rest of Latin America Opioid Tolerance Treatment Market Revenue, by End-User, 2017-2025 (USD Million)
    • 9.6. The Middle East and Africa
      • 9.6.1. The Middle East and Africa Opioid Tolerance Treatment Market Revenue, by Drug, 2017-2025 (USD Million)
      • 9.6.2. The Middle East and Africa Opioid Tolerance Treatment Market Revenue, by Opioid Tolerance Type, 2017-2025 (USD Million)
      • 9.6.3. The Middle East and Africa Opioid Tolerance Treatment Market Revenue, by Administration Route, 2017-2025 (USD Million)
      • 9.6.4. The Middle East and Africa Opioid Tolerance Treatment Market Revenue, by End-User, 2017-2025 (USD Million)
  •  
  • Chapter 10. Company Profile
    • 10.1. Boehringer Ingelheim International
      • 10.1.1. Overview
      • 10.1.2. Financials
      • 10.1.3. Product portfolio
      • 10.1.4. Business strategy
      • 10.1.5. Recent developments
    • 10.2. GlaxoSmithKline
      • 10.2.1. Overview
      • 10.2.2. Financials
      • 10.2.3. Product portfolio
      • 10.2.4. Business strategy
      • 10.2.5. Recent developments
    • 10.3. Teva Pharmaceutical Industries
      • 10.3.1. Overview
      • 10.3.2. Financials
      • 10.3.3. Product portfolio
      • 10.3.4. Business strategy
      • 10.3.5. Recent developments
    • 10.4. Mylan N.V.
      • 10.4.1. Overview
      • 10.4.2. Financials
      • 10.4.3. Product portfolio
      • 10.4.4. Business strategy
      • 10.4.5. Recent developments
    • 10.5. Otsuka Pharmaceutical
      • 10.5.1. Overview
      • 10.5.2. Financials
      • 10.5.3. Product portfolio
      • 10.5.4. Business strategy
      • 10.5.5. Recent developments
    • 10.6. Johnson & Johnson Services
      • 10.6.1. Overview
      • 10.6.2. Financials
      • 10.6.3. Product portfolio
      • 10.6.4. Business strategy
      • 10.6.5. Recent developments
    • 10.7. Aurobindo Pharma
      • 10.7.1. Overview
      • 10.7.2. Financials
      • 10.7.3. Product portfolio
      • 10.7.4. Business strategy
      • 10.7.5. Recent developments
    • 10.8. Pfizer
      • 10.8.1. Overview
      • 10.8.2. Financials
      • 10.8.3. Product portfolio
      • 10.8.4. Business strategy
      • 10.8.5. Recent developments
    • 10.9. Acorda Therapeutics
      • 10.9.1. Overview
      • 10.9.2. Financials
      • 10.9.3. Product portfolio
      • 10.9.4. Business strategy
      • 10.9.5. Recent developments
    • 10.10. ZydusCadila
      • 10.10.1. Overview
      • 10.10.2. Financials
      • 10.10.3. Product portfolio
      • 10.10.4. Business strategy
      • 10.10.5. Recent developments
      • 10.10.6. Business strategy
      • 10.10.7. Recent developments

Methodology

Free Analysis

Opioids are pain-relieving drugs that work with opioid receptors present in the human brain cell. The cell sends signals that change the perception of pain and uplifts the sense of pleasure in the body. Opioids are psychotropic substance derived from the opium poppy or developed in laboratories, such as heroin and morphine. Regular use or high dosage can create respiratory depression. The increasing number of chronic diseases, such as cancer, is one of the primary reasons for opioids overdose. According to the World Health Organization, in 2016, 65,632 people died due to overdose opioids, i.e., 21% more than the previous years. Every year, 0.65% of opioid-dependent individuals die due to opioid overdose, as per the W.H.O’s.

The increasing number of orthopedic surgeries is one of the main growth drivers of the global opioid tolerance treatment market. The growing occurrences of disease related to chronic pain, such as arthritis, cancer, and back pain is also propelling the opioids tolerance treatment market globally. Additionally, the escalating rise in the number of road accidents and trauma cases along with continuously growing cases of medical procedures is also boosting the demand for opioid-based pain management treatments, which, in turn, is fuelling the global opioid tolerance treatment market growth.

Global Opioid Tolerance Treatment Market

The global opioid tolerance treatment market is fragmented based on drug, administration route, opioid tolerance type, and end-user. Based on drug type, the market includes Alpha2-adrenoceptor agonists, NMDA antagonists, and others. The Alpha2-adrenoceptor agonists are further segmented into Clonidine, Tizanidine, and others. The NMDA antagonists segment is further divided into Dextromethorphan, Ketamine, and others. On the basis of opioid tolerance type, the global opioid tolerance treatment market is categorized into acquired tolerance and innate tolerance. By administration route, the market includes enteral and parenteral. By end-user, the global market comprises hospitals and ASCs, rehabilitation centers, and others.

The Asia Pacific region is expected to register a high growth rate in the global opioid tolerance treatment market, in terms of market share, over the estimated timeframe. North America accounted for the largest share of the global opioid tolerance treatment market in 2018, owing to the high prevalence of chronic diseases and pain associated with such diseases along with the increasing aging regional population, as geriatric people are more susceptible to pain and requires a high dose of opioids for pain relief.

Some major players operating in the global opioid tolerance treatment market are Pfizer, GlaxoSmithKline, Boehringer Ingelheim, Teva Pharmaceutical, Mylan, Otsuka Pharmaceutical, Johnson & Johnson, Aurobindo Pharma, Acorda Therapeutics, and Zydus Cadila.

}
Office Address

Corporate Office
Zion Market Research 244 Fifth Avenue, Suite N202 New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll Free No.1-855-465-4651

Asia Pacific Office
3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No 020-46277770

Contact #
US OFFICE NO +1-386-310-3803
US/CAN TOLL FREE +1-855-465-4651
Email: sales@zionmarketresearch.com